FOLH1 and prostate cancer: In addition, tumor growth inhibition was observed in a prostate cancer LNCaP xenograft model after a combined therapy with B-OT and 177Lu-PSMA-617 supporting the hypothesis that B-OT is a radiosensitizer (personal information, unpublished data).